• Contemporary treatment for arterial hypertension according to new European Guidelines: key aspects for pregnant women

Contemporary treatment for arterial hypertension according to new European Guidelines: key aspects for pregnant women

PERINATOLOGY AND PEDIATRIC. UKRAINE. 2018.2(74):7-12; doi 10.15574/PP.2018.74.7

Lymanska A. Yu., Dubrov S. O., Davydova Yu. V.
SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv
Bogomolets National Medical University, Kyiv, Ukraine
SI «Amosov National Institute of Cardiovascular Surgery of NAMS of Ukraine», Kyiv

The modern European Guidelines (2018) on the treatment of hypertension, which propose new targets of blood pressure values, increase the importance of out-of-office BP measurements, focus on less conservative treatment of elderly patients (BP <140–130/80 mm Hg), as well as the strategy of one pill that means the administration of combination drugs, introduce the policy of hypertensive crises treatment only by using drugs administered by intravenous injection. In the treatment of pregnants and during the planning for pregnancy, the using of beta-blockers is recommended. To date in the physicians' medical arsenal, there is a drug «Biblock» (manufactured by «Yuri-Farm»), which is a new intravenous selective β1-blocker of ultrashort action for the heart rate and blood pressure command control. The titrated route of administration makes it possible to select the safest and most effective dose of the drug, due to the ultrashort action it is possible to achieve a low frequency and rapid reversal of severe side effects after dose tapering or stopping of the drug taking.

Key words: arterial hypertension, pregnancy, European Guidelines, treatment, Biblock.

References

1. American College of Obstetricians and Gynecologists. (2013). Task Force on Hypertension in Pregnancy Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 122 (5):1122–1131. PMid:24150027

2. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. (2014). Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 348: 2301. https://doi.org/10.1136/bmj.g2301; PMid:24735917 PMCid:PMC3988319

3. Brown MA, Magee LA, Kenny LC, Karumanchi SA et al. (2018). Hypertensive Disorders of Pregnancy. ISSHP Classification, Diagnosis, and Management Recommendations for International Practice, Hypertension. 72: 24–43, Originally published June 13, 2018. https://doi.org/10.1016/j.preghy.2018.05.004; PMid:29803330

4. Krumpl G, Domanovits H, Stix G, Heinz G. (2012). Esmolol in Cardiology. Emergency and Critical-Care Medicine Journal fur Kardiologie — Austrian Journal of Cardiology. 19 (Supplementum A): 2–8.

5. Tranquilli AL, Dekker G, Magee L et al. (2014). The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 4 (2): 97–104. https://doi.org/10.1016/j.preghy.2014.02.001; PMid:26104417

6. Wiest DB, Haney JS. (2012, Jun. 1). Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin. Pharmacokinet. 51 (6): 347–356. https://doi.org/10.2165/11631590-000000000-00000.